UK markets closed

Zogenix, Inc. (0M3O.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
40.75+24.23 (+146.60%)
At close: 03:58PM GMT
Sign in to post a message.
  • H
    Hervelo
    What's up ?
  • S
    Steven
    Do you guys think the rise is going to continue? Should I buy some more?
  • J
    JD
    Hopefully, we get some consolidation above 13.00. Closing a weekly near $15 will be key.
  • J
    JD
    I like the recent technicals. But we’re getting closer to the weekly 20, which has been ZGNX resistance since 5/25/2020. Be vigilant and good luck.
  • S
    SAN
    This can touch $23 in short range.
  • S
    SAN
    This is dirt cheap, so grab this one before it jumps..
  • P
    Park
    Any reasons why this is down 70% in a year? Looking to open a position. What catalysts are in the next few qtrs? Thx guys
  • J
    JD
    Have we found the base? If not, should be close based on 2017 support level.
  • 💊C
  • f
    fred
    I hold 10 shares because I am a true believer. :)
  • 💊C
    First time in years we haven’t taken a big hit after earnings. Priority Review for LGS coming, then we’ll push past $20. We’re almost there!
  • c
    cd
    5 years and this is up only 10%.
  • Y
    Yahoo Finance Insights
    Zogenix is up 5.49% to 12.50
  • D
    David
    Mizuho Securities’ Difei Yang also reiterated her bullish perspective on the stock saying “We note that this is a broader patient designation than the Phase 3 trial, which consisted of subjects age 2-18.” The analyst points out that the labeling includes a boxed warning which states that Fintepla is associated with valvular heart disease (VHD) and pulmonary arterial hypertension (PAH)- but says that this is also ‘as expected’.

    Yang already had a 100% probability of success on the indication and so reaffirmed her buy rating and $64 price target. This suggests shares can more than double from current levels.
  • 💊C
    Stifel analyst Paul Matteis reiterated a Buy rating and $68.00 price target on Zogenix, Inc. (NASDAQ: ZGNX) after conducting an epilepsy physician survey that suggests that ZGNX shares are undervalued on the potential of Fintepla in Dravet and LGS. The survey group consisted of 25 epileptologists/neurologists who treat 11,400 epilepsy patients, including 480 and 1209 with Dravet and LGS, respectively.

    The analyst stated "Feedback on Dravet, even though familiarity with Fintepla is still variable is generally affirming to this being a best-in-class drug. Physicians are projecting slightly over 50% penetration at peak; those who stated they know the data "very well" expect Fintepla to be utilized in 54% of their Dravet patients, and in the aggregate respondents expect 18%/32% of Dravet patients on drug at 6/12 months".
  • S
    SAN
    Need help on what should be done on my situation if my purchases are 45 plus per share for few K shares.

    1. Sell everything to avoid further losses.
    2. Sell part of it to avoid further losses.
    3. Hold, but it may go further down.
    4. Sell to buy something else.

    I have losses of more than $81k on this.

    Any serious input is appreciated.

    Thanks,
  • H
    Heather
    The FDA’s approval was based on data from two placebo-controlled phase III studies and safety data from an extension study. Fintepla will be launched through a restricted distribution program, called the Fintepla Risk Evaluation and Mitigation Strategy (REMS) Program. The drug is expected to be available through Zogenix's specialty pharmacy partner by the end of July. Price target for ZGNX is $50 and is currently trading between $26 - $28. The Markets Red day in general at 500 points down has created an amazing entry price as of 6-26-20. I see this at $36 by Monday.
  • C
    Chloe
    $ZGNX | Technical Analysis (7/2/2019) by #TMG | TradingView Link: https://www.tradingview.com/chart/ZGNX/4KACFWaO-ZOGENIX-INC-STAGES-HUGE-REVERSAL-BUT-WAIT/
    BULLISH BUT BECOMING CLOSE TO OVERSOLD, NO NEED TO RUSH IN AT THIS CRITICAL POINT. PULLBACK POSSIBLE FROM .65 FIB VOLUME HAS DECLINED, BEARISH FDA APPROVAL TIPPED TO BE RECEIVED ON NEW SUBMISSION AVERAGE ANALYSTS PRICE TARGET $66 AVERAGE ANALYSTS
    BULLISH BUT BECOMING CLOSE TO OVERSOLD, NO NEED TO RUSH IN AT THIS CRITICAL POINT. PULLBACK POSSIBLE FROM .65 FIB VOLUME HAS DECLINED, BEARISH FDA APPROVAL TIPPED TO BE RECEIVED ON NEW SUBMISSION AVERAGE ANALYSTS PRICE TARGET $66 AVERAGE ANALYSTS
    www.tradingview.com
  • D
    David
    Zgnx has a commercial team already rolled out across the US. FINTEPLA will soon be a excellent stream of revenue. GW took about 2 months after Epidiolex was FDA approved to gap up. It accounted for nearly all GW’s sales last year, 300m. GW trading in $120’s. No doubt ZOGENIX will be there very soon.
  • E
    Eric J
    I have a positive feeling. Peeps are just getting nervous. After market we will be happy we stayed with this.. after reading phase 3 results, seems solid to me and many can benefit from this too.